JP2020142995A - External preparations for skin - Google Patents
External preparations for skin Download PDFInfo
- Publication number
- JP2020142995A JP2020142995A JP2019038440A JP2019038440A JP2020142995A JP 2020142995 A JP2020142995 A JP 2020142995A JP 2019038440 A JP2019038440 A JP 2019038440A JP 2019038440 A JP2019038440 A JP 2019038440A JP 2020142995 A JP2020142995 A JP 2020142995A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- gene expression
- ubiquinone
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 23
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 23
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 22
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 17
- 239000012138 yeast extract Substances 0.000 claims abstract description 17
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 15
- 239000000419 plant extract Substances 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 241000218996 Passiflora Species 0.000 claims abstract description 5
- 241001083505 Punica Species 0.000 claims abstract description 4
- 235000005807 Nelumbo Nutrition 0.000 claims abstract description 3
- 244000294611 Punica granatum Species 0.000 claims description 9
- 235000014360 Punica granatum Nutrition 0.000 claims description 7
- 239000000284 extract Substances 0.000 abstract description 25
- 238000007665 sagging Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 241000209445 Nelumbonaceae Species 0.000 abstract description 4
- 241000219991 Lythraceae Species 0.000 abstract 1
- 241000218995 Passifloraceae Species 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 34
- 230000001737 promoting effect Effects 0.000 description 32
- 238000000605 extraction Methods 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 14
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 10
- 108010087806 Carnosine Proteins 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 10
- 229940044199 carnosine Drugs 0.000 description 10
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 10
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 229940109529 pomegranate extract Drugs 0.000 description 6
- 101150000629 TGFB1 gene Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000020689 passion flower extract Nutrition 0.000 description 5
- 229940001884 passion flower extract Drugs 0.000 description 5
- 101150102163 ATG7 gene Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- -1 homoantherin Chemical compound 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 101150066859 ubiad1 gene Proteins 0.000 description 4
- 101150102644 Angpt1 gene Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004957 autophagosome Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 description 2
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 101150073922 ATG12 gene Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101150088671 Becn1 gene Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000178951 Endomyces Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101100129000 Homo sapiens LTBP4 gene Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101150027754 Map1lc3a gene Proteins 0.000 description 2
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 description 2
- 244000288157 Passiflora edulis Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 101150008009 coq-2 gene Proteins 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- BSXFOBDOGHFWOC-KRCBVYEFSA-N (2S)-1-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@H](NC(=O)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 BSXFOBDOGHFWOC-KRCBVYEFSA-N 0.000 description 1
- KQEQPUBSXXOUGC-MLCQCVOFSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-acetylpyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(C)=O)C(O)=O KQEQPUBSXXOUGC-MLCQCVOFSA-N 0.000 description 1
- CGPSWQBETUSORI-MTUNXJOQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-6-amino-N-[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O CGPSWQBETUSORI-MTUNXJOQSA-N 0.000 description 1
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 1
- YXIBXUGCDCJBPD-JYJNAYRXSA-N (2s)-2,6-diamino-n-[2-[[(2s)-1-[[(2s)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]hexanamide Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 YXIBXUGCDCJBPD-JYJNAYRXSA-N 0.000 description 1
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 description 1
- OFGVZFQUFJYSGS-CPDXTSBQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OFGVZFQUFJYSGS-CPDXTSBQSA-N 0.000 description 1
- LAMPQFOTAITAOO-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-(hexanoylamino)pentanoyl]amino]propanoyl]amino]hexanamide Chemical compound CCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCC)C(N)=O LAMPQFOTAITAOO-JYJNAYRXSA-N 0.000 description 1
- ZHUJMSMQIPIPTF-JMBSJVKXSA-N (2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-JMBSJVKXSA-N 0.000 description 1
- SAVSLMGBKQKUAV-JYJNAYRXSA-N (2s)-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-3-methyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound FC(F)(F)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 SAVSLMGBKQKUAV-JYJNAYRXSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- ITIMHIATVYROGF-XWUOBKMESA-N (3S)-3-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O ITIMHIATVYROGF-XWUOBKMESA-N 0.000 description 1
- QNZANUZIBYJBIN-XSWJXKHESA-N (3s)-3-[[(2s)-2-acetamido-5-amino-5-oxopentanoyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNZANUZIBYJBIN-XSWJXKHESA-N 0.000 description 1
- OSFKACNWYBVEBJ-IWZJHKITSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2s)-1 Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 OSFKACNWYBVEBJ-IWZJHKITSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 102000012035 Autophagy-Related Protein 12 Human genes 0.000 description 1
- 108010061408 Autophagy-Related Protein 12 Proteins 0.000 description 1
- 241000722885 Brettanomyces Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241001508787 Citeromyces Species 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- 101800002922 Decapeptide 2 Proteins 0.000 description 1
- 241001542272 Endomycetaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000235167 Eremascus Species 0.000 description 1
- 241001465321 Eremothecium Species 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- 241001149698 Lipomyces Species 0.000 description 1
- 241001508815 Lodderomyces Species 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- 241001123674 Metschnikowia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000193596 Nadsonia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101800001149 Octapeptide 2 Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000235652 Pachysolen Species 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001489223 Saccharomycodes Species 0.000 description 1
- 241000235003 Saccharomycopsis Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
- 241000193620 Wickerhamia Species 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 229940086540 acetyl tetrapeptide-9 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000005033 autophagosome formation Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、高いたるみ改善効果を発揮する皮膚外用剤に関する。 The present invention relates to an external preparation for skin that exhibits a high sagging improving effect.
肌のたるみは真皮の弾力性の低下、皮膚脂肪組織の支持力の低下、さらには皮膚を支える筋力の低下等により生じる。この肌老化の一つであるたるみを改善するために肌のハリ・弾力を持たせる皮膚外用剤に配合する成分の検討が行われてきた。これまでユビキノン及びペプチドがシワ防止化粧料に用いられることが知られている（特許文献１）。しかしながら、たるみ改善効果については十分に検討されていなかった。 The sagging of the skin is caused by a decrease in the elasticity of the dermis, a decrease in the supporting force of the adipose tissue of the skin, and a decrease in the muscle strength supporting the skin. In order to improve sagging, which is one of the skin aging, the ingredients to be added to the external preparation for skin to give the skin firmness and elasticity have been studied. It has been known that ubiquinone and peptides are used in anti-wrinkle cosmetics (Patent Document 1). However, the effect of improving sagging has not been sufficiently examined.
本発明は、ユビキノン及びペプチドを含有する皮膚外用剤において、特定の植物抽出物及び酵母エキスから選択される１種又は２種以上を併用することにより、高いたるみ改善効果を発揮する皮膚外用剤を提供することを課題とする。 The present invention provides a skin external preparation containing ubiquinone and a peptide, which exhibits a high sagging improving effect by using one or more selected from a specific plant extract and yeast extract in combination. The challenge is to provide.
本発明は、
下記（Ａ）〜（Ｃ）を含有する皮膚外用剤
（Ａ）ユビキノン
（Ｂ）ペプチド
（Ｃ）ハス科ハス属（Nelumbo）植物抽出物、トケイソウ科トケイソウ属（Passiflora）植物抽出物、ザクロ科ザクロ属（Punica）植物抽出物及び酵母エキスから選択される１種又は２種以上
を提供する。
The present invention
External skin preparation containing the following (A) to (C) (A) Ubiquinone (B) Peptide (C) Lotus family Lotus (Nelumbo) plant extract, Passiflora plant extract, Pomegranate family Pomegranate Provided is one or more selected from the genus (Punica) plant extract and yeast extract.
本発明は、ユビキノン及びペプチドを含有する皮膚外用剤において、特定の植物抽出物及び酵母エキスから選択される１種又は２種以上を併用することにより、高いたるみ改善効果を発揮する。 The present invention exerts a high sagging improving effect in a skin external preparation containing ubiquinone and a peptide by using one or more selected from a specific plant extract and yeast extract in combination.
ハス抽出物はコラーゲン等の細胞外マトリックスタンパク質の産生促進に関与するTGFB1遺伝子発現促進効果、オートファゴソームの形成に関与するATG12遺伝子発現促進効果、血管の新生や安定化に関与するANGPT1遺伝子発現効果を発揮する。 Hass extract has a TGFB1 gene expression promoting effect involved in promoting the production of extracellular matrix proteins such as collagen, an ATG12 gene expression promoting effect involved in the formation of autophagosomes, and an ANGPT1 gene expression promoting effect involved in angiogenesis and stabilization. Demonstrate.
クダモノトケイソウ抽出物はコラーゲン等の細胞外マトリックスタンパク質の産生促進に関与するTGFB1遺伝子発現促進効果、オートファゴソームの形成に関与するBECN1遺伝子発現促進効果，MAP1LC3A遺伝子発現促進効果，ATG7遺伝子発現促進効果，ATG12遺伝子発現促進効果、血管の新生や安定化に関与するANGPT1遺伝子発現促進効果、ユビキノンの合成に関与するUBIAD1遺伝子発現促進効果，COQ2遺伝子発現促進効果を発揮する。 Kudamonotokeisou extract has a TGFB1 gene expression promoting effect involved in promoting the production of extracellular matrix proteins such as collagen, a BECN1 gene expression promoting effect involved in autophagosome formation, a MAP1LC3A gene expression promoting effect, an ATG7 gene expression promoting effect, and ATG12. It exerts a gene expression promoting effect, an ANGPT1 gene expression promoting effect involved in vascular neoplasia and stabilization, a UBIAD1 gene expression promoting effect involved in ubiquinone synthesis, and a COQ2 gene expression promoting effect.
ザクロ抽出物はコラーゲン等の細胞外マトリックスタンパク質の産生促進に関与するTGFB1遺伝子発現促進効果、弾性線維形成の促進に関与するLTBP4遺伝子発現促進効果、オートファゴソームの形成に関与するATG7遺伝子発現促進効果、ユビキノンの合成に関与するUBIAD1遺伝子発現効果を発揮する。 Pomegranate extract has a TGFB1 gene expression promoting effect involved in promoting the production of extracellular matrix proteins such as collagen, an LTBP4 gene expression promoting effect involved in promoting elastic fiber formation, and an ATG7 gene expression promoting effect involved in the formation of autophagosomes. It exerts the UBIAD1 gene expression effect involved in the synthesis of ubiquinone.
酵母エキスはコラーゲン等の細胞外マトリックスタンパク質の産生促進に関与するTGFB1遺伝子発現促進効果、オートファゴソームの形成に関与するATG7遺伝子発現促進効果、ユビキノンの合成に関与するUBIAD1遺伝子発現促進効果を発揮する。 Yeast extract exerts a TGFB1 gene expression promoting effect involved in promoting the production of extracellular matrix proteins such as collagen, an ATG7 gene expression promoting effect involved in the formation of autophagosomes, and a UBIAD1 gene expression promoting effect involved in ubiquinone synthesis.
以下本発明を実施するための形態を説明する。 Hereinafter, embodiments for carrying out the present invention will be described.
本発明の皮膚外用剤は、化粧品、医薬部外品、医薬品等のいずれの用途にも用いられ得る。 The external preparation for skin of the present invention can be used for any of cosmetics, quasi-drugs, pharmaceuticals and the like.
本発明に用いられるユビキノンは、別名コエンザイムＱ10とも呼ばれ、生体内に存在するエネルギーを生産するためのエネルギー代謝に関わっている補酵素のひとつである。ベンゾキノン型の酸化型とヒドロキノン型の還元型があり、還元型であるユビキノールとして配合しても良い。製造方法は、合成、微生物による発酵等方法を問わず、何れのものも使用することができる。 Ubiquinone used in the present invention, also known as coenzyme Q10, is one of the coenzymes involved in energy metabolism for producing energy existing in the living body. There are an oxidized form of benzoquinone type and a reduced form of hydroquinone type, and they may be blended as a reduced form of ubiquinol. Any manufacturing method can be used regardless of the method such as synthesis or fermentation by microorganisms.
本発明に用いられるユビキノンの配合量は０．００００１質量％〜０．３質量％が好ましく、より好ましくは０．００００１質量％〜０．１質量％である。 The blending amount of ubiquinone used in the present invention is preferably 0.00001% by mass to 0.3% by mass, and more preferably 0.00001% by mass to 0.1% by mass.
本発明に用いられるペプチドは、アミノ酸２〜１０個が結合したペプチド及びその誘導体である。例えば、カルノシン，アンセリン，ホモアンセリン，アラニルグルタミン，ジペプチド−２，ジペプチド−４，アセチルジペプチド−１セチル，酢酸ヘキサノイルジペプチド−３ノルロイシン，トリペプチド−１，トリペプチド−２，トリペプチド−３，トリペプチド−５，トリフルオロアセチルトリペプチド−２，パルミトイルトリペプチド−１，パルミトイルトリペプチド−５，パルミトイルトリペプチド−８，トリペプチド−１０シトルリン，グルタチオン，カプロオイルテトラペプチド−３，アセチルテトラペプチド−２，アセチルテトラペプチド−５，アセチルテトラペプチド−９，アセチルテトラペプチド−１１，アセチルテトラペプチド−１５，パルミトイルテトラペプチド-７，ペンタペプチド−３，ペンタペプチド−１８，パルミトイルペンタペプチド−４，ヘキサペプチド−２，ヘキサペプチド−３，ヘキサペプチド−９，ヘキサペプチド−１０，アセチルヘキサペプチド−１，アセチルヘキサペプチド−８，アセチルグルタミニルヘプタペプチド−１，オクタペプチド−２，ノナペプチド−１，オリゴペプチド−６，デカペプチド−２，デカペプチド−４，アセチルデカペプチド−３等を用いることができる。特にはカルノシンを用いることが好ましい。さらには、カルノシン，トリフルオロアセチルトリペプチド，パルミトイルトリペプチド及びパルミトイルテトラペプチドを併用することが好ましい。 The peptides used in the present invention are peptides to which 2 to 10 amino acids are bound and derivatives thereof. For example, carnosin, anserine, homoantherin, alanylglutamine, dipeptide-2, dipeptide-4, acetyldipeptide-1 cetyl, hexanoyldipeptide-3 norleucine, tripeptide-1, tripeptide-2, tripeptide-3, Tripeptide-5, Trifluoroacetyl Tripeptide-2, Palmitoyl Tripeptide-1, Palmitoyl Tripeptide-5, Palmitoyl Tripeptide-8, Tripeptide-10 Citrulin, Glutathion, Caprooil Tetrapeptide-3, Acetyl Tetrapeptide -2, Acetyltetrapeptide-5, Acetyltetrapeptide-9, Acetyltetrapeptide-11, Acetyltetrapeptide-15, Palmitoyltetrapeptide-7, Pentapeptide-3, Pentapeptide-18, Palmitoylpentapeptide-4, Hexa Peptide-2, Hexapeptide-3, Hexapeptide-9, Hexapeptide-10, Acetylhexapeptide-1, Acetylhexapeptide-8, Acetylglutaminylheptapeptide-1, Octapeptide-2, Nonapeptide-1, Oligopeptide -6, Decapeptide-2, Decapeptide-4, Acetyldecapeptide-3 and the like can be used. In particular, it is preferable to use carnosine. Furthermore, it is preferable to use carnosine, trifluoroacetyl tripeptide, palmitoyl tripeptide and palmitoyl tetrapeptide in combination.
本発明に用いられるペプチドの配合量は０．００１質量％〜１０質量％が好ましく、より好ましくは０．０１質量％〜０．１質量％である。 The blending amount of the peptide used in the present invention is preferably 0.001% by mass to 10% by mass, more preferably 0.01% by mass to 0.1% by mass.
本発明に用いられるハス科ハス属（Nelumbo）植物の抽出物は、ハス（N.nucifera）の他、同属植物の抽出物を用いることができる。ハス（N.nucifera）は池や水田、堀等に栽培される多年生水草で、根茎は白色で長細く、先端部は肥厚している。葉は長い葉柄を持つ。抽出部位としては根，茎，葉，花，果実，種子，雄蕊，胎座，胚芽等の各部位を用いることができるが、花を用いることが好ましい。 As the extract of the Nelumbonaceae plant used in the present invention, an extract of the same genus plant can be used in addition to the lotus (N. nucifera). Sacred lotus (N. nucifera) is a perennial aquatic plant cultivated in ponds, paddy fields, moats, etc. The rhizome is white and elongated, and the tip is thickened. The leaves have long petioles. As the extraction site, roots, stems, leaves, flowers, fruits, seeds, stamens, placentations, germs and the like can be used, but it is preferable to use flowers.
本発明において、上記植物は生のまま抽出に供してもよいが、抽出効率を考えると、細切，乾燥，粉砕等の処理を行った後に抽出を行うことが好ましい。抽出は、抽出溶媒に浸漬して行う。抽出効率を上げるため撹拌を行う、あるいは抽出溶媒中でホモジナイズしてもよい。抽出温度としては、５℃程度から抽出溶媒の沸点以下の温度とするのが適切である。抽出時間は抽出溶媒の種類や抽出温度によっても異なるが、４時間〜１４日間程度とするのが適切である。 In the present invention, the above-mentioned plants may be subjected to extraction as they are, but in consideration of extraction efficiency, it is preferable to perform extraction after performing treatments such as shredding, drying and crushing. Extraction is performed by immersing in an extraction solvent. Stirring may be performed to increase the extraction efficiency, or homogenization may be performed in an extraction solvent. It is appropriate that the extraction temperature is from about 5 ° C. to a temperature equal to or lower than the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it to about 4 hours to 14 days.
抽出溶媒としては、例えば水、低級アルコール（メタノール，エタノール，プロパノール，イソプロパノール等）、多価アルコール（1,3-ブチレングリコール，プロピレングリコール，ジプロピレングリコール，グリセリン等）、エーテル類（エチルエーテル，プロピルエーテル等）、エステル類（酢酸エチル，酢酸ブチル等）、ケトン類（アセトン，エチルメチルケトン等）等の極性有機溶媒が挙げられ、これらより１種又は２種以上を選択して用いる。また、生理食塩水，リン酸緩衝液，リン酸緩衝生理食塩水等を用いてもよい。 Examples of the extraction solvent include water, lower alcohols (methanol, ethanol, propanol, isopropanol, etc.), polyhydric alcohols (1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, etc.), ethers (ethyl ether, propyl, etc.). Examples thereof include polar organic solvents such as ethers (ether, etc.), esters (ethyl acetate, butyl acetate, etc.), ketones (acetone, ethyl methyl ketone, etc.), and one or more of these are selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline and the like may be used.
上記溶媒による抽出物は、そのままでも用いることができるが、濃縮，乾固したものを水や極性溶媒に再度溶解したり、或いはそれらの皮膚生理機能向上作用を損なわない範囲で脱色，脱臭，脱塩等の精製処理を行ったり、カラムクロマトグラフィーによる分画処理を行った後に用いてもよい。また、抽出物を酸、アルカリ、酵素等を用いて加水分解したものを用いてもよい。また保存のため、精製処理の後凍結乾燥し、用時に溶媒に溶解して用いることもできる。また、リポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。 The extract with the above solvent can be used as it is, but it is decolorized, deodorized, and deodorized as long as the concentrated and dried product is re-dissolved in water or a polar solvent, or their skin physiological function improving effects are not impaired. It may be used after purification treatment of salt or the like or fractionation treatment by column chromatography. Further, the extract obtained by hydrolyzing the extract with an acid, alkali, enzyme or the like may be used. For storage, it can also be purified, freeze-dried, and dissolved in a solvent before use. It can also be used by being encapsulated in a vesicle such as a liposome or a microcapsule.
本発明に用いられるトケイソウ科トケイソウ属（Passioflora）植物の抽出物は、クダモノトケイソウ（P.edulis）の他、同属植物の抽出物を用いることができる。クダモノトケイソウ（P.edulis）はつる性の多年草で、葉は互生で掌状であり、茎の各節に巻きひげと托葉がある。花は白色あるいは帯紫色で、果実は球形もしくは卵形で深紫色に熟す。抽出部位としては、果実，果皮，花，種子等の各部位を用いることができるが、果実を用いることが好ましい。抽出方法としては、ハス科ハス属植物の抽出物を得る際と同様である。 As the extract of the Passioflora plant of the Passioflora family used in the present invention, an extract of the same genus plant can be used in addition to the Passioflora (P. edulis). Passionflower (P. edulis) is a climbing perennial with alternate, palm-shaped leaves and tendrils and leaves on each node of the stem. The flowers are white or purplish, and the fruits are spherical or oval and ripen deep purple. As the extraction site, each site such as fruit, pericarp, flower, and seed can be used, but it is preferable to use fruit. The extraction method is the same as when obtaining an extract of a plant belonging to the genus Lotus of the family Nelumbonaceae.
本発明に用いられるザクロ科ザクロ属（Punica）植物の抽出物は、ザクロ（P.granatum）の他、同属植物の抽出物を用いることができる。ザクロ（P.granatum）は小高木で分枝が多く、とげがある。葉はほぼ対生し、長楕円形をしている。抽出部位としては、果実，果皮，果汁，樹皮，花，葉等の各部位を用いることができるが、果実を用いることが好ましい。抽出方法としては、ハス科ハス属植物の抽出物を得る際と同様である。 As the extract of the pomegranate genus (Punica) plant used in the present invention, in addition to the pomegranate (P. granatum), the extract of the same genus plant can be used. Pomegranate (P. granatum) is a small tree with many branches and thorns. The leaves are almost opposite and oblong. As the extraction site, each site such as fruit, pericarp, juice, bark, flower, and leaf can be used, but it is preferable to use fruit. The extraction method is the same as when obtaining an extract of a plant belonging to the genus Lotus of the family Nelumbonaceae.
本発明に用いられる上述の植物抽出物の配合量としては、好ましくは０．００００１質量％〜５質量％、特に０．０００１質量％〜１質量％の範囲である。この範囲であれば、製剤及び製剤中の植物の経時安定性に影響を及ぼすことが無く、より高い効果を発揮させることができる。 The blending amount of the above-mentioned plant extract used in the present invention is preferably in the range of 0.00001% by mass to 5% by mass, particularly 0.0001% by mass to 1% by mass. Within this range, the preparation and the stability of the plant in the preparation over time are not affected, and a higher effect can be exhibited.
本発明に用いられる酵母エキスとしては、酵母の極性溶媒による抽出物、酵母を自己消化，酸加水分解又は酵素分解等により溶菌させた後ろ過したもの、あるいは前記溶菌液を乾燥し、それより極性溶媒で抽出した物を用いることができる。酵母としては、Eremascus属，Endomyces属等のEndomycetaceae科に属する酵母や、Candida属，Schizosaccharomyces属，Nadsonia属，Saccharomycodes属，Hanseniaspora属，Wickerhamia属，Saccharomyces属，Kluyveromyces属，Lodderomyces属，Wingea属，Endomycopsis属，Pichia属，Hansenula属，Pachysolen属，Citeromyces属，Debaryomyces属，Schwanniomyces属，Dekkera属，Saccharomycopsis属，Lipomyces属等のSaccharomycoideae科に属する酵母、Spermophthora属，Eremothecium属，Crebrothecium属，Ashbya属，Nematospora属，Metschnikowia属，Coccidiascus属等のSpermophthoraceae科に属する酵母等の子のう菌酵母が例示される。好ましくはCandida属である。 The yeast extract used in the present invention includes an extract of yeast in a polar solvent, yeast lysed by autolysis, acid hydrolysis, enzymatic decomposition, etc. and then filtered, or the lysate solution is dried and more polar. A product extracted with a solvent can be used. Yeasts include yeasts belonging to the Endomycetaceae family such as Eremascus and Endomyces, Candida, Schizosaccharomyces, Nadsonia, Saccharomycodes, Hanseniaspora, Wickerhamia, Saccharomyces, Kluyveromyces, Lodderomyces, and Endomyces. , Pichia, Hansenula, Pachysolen, Citeromyces, Debaryomyces, Schwanniomyces, Dekkera, Saccharomycopsis, Lipomyces and other Saccharomycoideae yeasts, Spermophthora, Eremothecium, Crebrothecium, Examples include ascospores such as yeasts belonging to the family Spermophthoraceae such as the genus Metschnikowia and the genus Coccidiascus. It is preferably of the genus Candida.
本発明に用いられる酵母エキスの配合量は特に限定されないが、０．０００１質量％〜１０質量％が好ましい。市販のAC YEAST CYTSOL PET（株式会社GSIクレオス製）、BETA VERA（BROOKS社製）、GluCare N（コスモファーム株式会社製）、YG-1-W（一丸ファルコス株式会社製）、アクア バイオミン 2（BROOKS社製）、イーストラップ（キリンビール株式会社製）、イーストリキッド（一丸ファルコス株式会社製）、イーストリキッド ZB（一丸ファルコス株式会社製）、イーストリキッド B（一丸ファルコス株式会社製）、イーストリキッド TRX（一丸ファルコス株式会社製）、CELLDETOX（登録商標）PX（Silab社製）、Biofactor HSP PE（Ashland社製）、ハイチオンエキス（登録商標）YH-15（株式会社興人製）、酵母抽出液BG（丸善製薬株式会社製）、チトカタライザー（BIODELL BIOCHEMICAL社製）、チトカタライザー W（BIODELL BIOCHEMICAL社製）、チトカタライザー YSC（BIODELL BIOCHEMICAL社製）、DISMUTIN（登録商標）-JPF（DSM株式会社製）等を用いることもできる。 The blending amount of the yeast extract used in the present invention is not particularly limited, but is preferably 0.0001% by mass to 10% by mass. Commercially available AC YEAST CYTSOL PET (manufactured by GSI Creos Co., Ltd.), BETA VERA (manufactured by BROOKS), GluCare N (manufactured by Cosmo Farm Co., Ltd.), YG-1-W (manufactured by Ichimaru Falcos Co., Ltd.), Aqua Biomin 2 (manufactured by BROOKS) East Liquid (manufactured by Kirin Brewery Co., Ltd.), East Liquid (manufactured by Ichimaru Falcos Co., Ltd.), East Liquid ZB (manufactured by Ichimaru Falcos Co., Ltd.), East Liquid B (manufactured by Ichimaru Falcos Co., Ltd.), East Liquid TRX (manufactured by Ichimaru Falcos Co., Ltd.) Ichimaru Falcos Co., Ltd.), CELLDETOX (registered trademark) PX (Silab), Biofactor HSP PE (Ashland), Hythion Extract (registered trademark) YH-15 (Kojin Co., Ltd.), Yeast extract BG (Maruzen Pharmaceutical Co., Ltd.), Chitocatalyzer (BIODELL BIOCHEMICAL), Chitocatalyzer W (BIODELL BIOCHEMICAL), Chitocatalyzer YSC (BIODELL BIOCHEMICAL), DISMUTIN (registered trademark)-JPF (DSM stock) (Made by company) etc. can also be used.
本発明の皮膚外用剤には上述の必須成分の他に、必要に応じて通常皮膚外用剤に配合される、水性成分、油性成分、保湿剤、色素、界面活性剤、紫外線吸収剤、増粘剤、美容成分、香料、高分子物質、防菌防黴剤、アルコール類、粉体、スクラブ剤、生体由来成分等を適宜配合することができる。 In addition to the above-mentioned essential components, the skin external preparation of the present invention usually contains an aqueous component, an oily component, a moisturizer, a pigment, a surfactant, an ultraviolet absorber, and a thickening agent, which are usually added to the skin external preparation as needed. Agents, beauty ingredients, fragrances, polymer substances, antibacterial and antifungal agents, alcohols, powders, scrubbing agents, biological ingredients and the like can be appropriately blended.
本発明の皮膚外用剤は、例えば、ローション剤、乳剤、軟膏の剤型で用いることができる。また、本発明の皮膚外用剤は製造方法を問わない。 The external preparation for skin of the present invention can be used in, for example, lotions, emulsions, and ointments. In addition, the external preparation for skin of the present invention may be produced regardless of the manufacturing method.
以下、実施例により本発明を具体的に説明するが、これにより本発明の範囲が限定されるものではない。なお、配合量は特に断りのない限り質量％である。 Hereinafter, the present invention will be specifically described with reference to Examples, but the scope of the present invention is not limited thereto. The blending amount is mass% unless otherwise specified.
まず、使用した各成分の調製例を示す。 First, a preparation example of each component used is shown.
［ユビキノン］
ユビキノンとして、株式会社カネカ製のユビデカレノン「カネカ」（登録商標）を用いた。
[Ubiquinone]
As the ubiquinone, Kaneka Corporation's ubidecalenone "Kaneka" (registered trademark) was used.
［ハス抽出物］
５０％BG水溶液を用いて得られたエキスをろ過してハス抽出物とした。
[Lotus extract]
The extract obtained using a 50% BG aqueous solution was filtered to obtain a lotus extract.
［クダモノトケイソウ抽出物］
３０％BG水溶液を用いて得られたエキスをろ過してクダモノトケイソウ抽出物とした。
[Passionflower extract]
The extract obtained using a 30% BG aqueous solution was filtered to obtain a Passionflower extract.
［ザクロ抽出物］
５０％BG水溶液を用いて得られたエキスをろ過してザクロ抽出物とした。
[Pomegranate extract]
The extract obtained using a 50% BG aqueous solution was filtered to obtain a pomegranate extract.
［酵母抽出物］
酵母抽出物として、Silab社製のCELLDETOX（登録商標）PXを用いた。
[Yeast extract]
CELLDETOX® PX manufactured by Silab was used as the yeast extract.
［TGFB1遺伝子発現促進作用、LTBP4遺伝子発現促進作用、BECN1遺伝子発現促進作用、MAP1LC3A遺伝子発現促進作用、ATG7遺伝子発現促進作用、ATG12遺伝子発現促進作用、ANGPT1遺伝子発現促進作用、UBIAD1遺伝子発現促進作用、COQ2遺伝子発現促進作用］
ヒト線維芽細胞を６×１０５個/ウェルとなるように６ウェルプレートに播種し、０．５％ＦＢＳを含むＤＭＥＭ培地にて一晩培養した。ユビキノン、カルノシン、植物抽出物又は酵母エキスを表１及び表２に示した濃度になるように添加した培地に交換し、３７℃、５％ CO2インキュベーター内で２４時間培養した。採取した細胞から、市販のＲＮＡ抽出キット（Quick Gene RNA Cultured Cell HC Kit S）を使用してＲＮＡを抽出し、ｃＤＮＡ合成後に下記のプライマーを使用してサイバーグリーン法によるリアルタイムＰＣＲにより遺伝子発現を確認した。なお、内部標準としてＧＡＰＤＨを使用した。培地に溶解した試料を表１及び表２に示した。各作用は表４〜表７にそれぞれ示した。なおｍＲＮＡ発現量は、各抽出物無添加の場合の発現量を１とした相対値で示した。
[TGFB1 gene expression promoting action, LTBP4 gene expression promoting action, BECN1 gene expression promoting action, MAP1LC3A gene expression promoting action, ATG7 gene expression promoting action, ATG12 gene expression promoting action, ANGPT1 gene expression promoting action, UBIAD1 gene expression promoting action, COQ2 Gene expression promoting action]
Human fibroblasts were seeded in 6-well plates at 6 × 10 5 cells / well and cultured overnight in DMEM medium containing 0.5% FBS. Ubiquinone, carnosine, plant extract or yeast extract was replaced with the medium added to the concentrations shown in Tables 1 and 2, and cultured at 37 ° C. in a 5% CO 2 incubator for 24 hours. RNA is extracted from the collected cells using a commercially available RNA extraction kit (Quick Gene RNA Cultured Cell HC Kit S), and gene expression is confirmed by real-time PCR by the cyber green method using the following primers after cDNA synthesis. did. GAPDH was used as an internal standard. The samples dissolved in the medium are shown in Tables 1 and 2. Each action is shown in Tables 4 to 7, respectively. The mRNA expression level was shown as a relative value with the expression level when each extract was not added as 1.
表４に示した通り、ユビキノン、カルノシン及びハス抽出物を含有する試料６を添加することにより、試料１、試料２（それぞれの有効成分量は倍量となる）を添加する場合と比較して、たるみ改善に関わる遺伝子発現量が相乗的に向上していた。 As shown in Table 4, by adding sample 6 containing ubiquinone, carnosine and lotus extract, compared with the case of adding sample 1 and sample 2 (the amount of each active ingredient is doubled). , The gene expression level related to the improvement of sagging was synergistically improved.
表５に示した通り、ユビキノン、カルノシン及びクダモノトケイソウ抽出物を含有する試料７を添加することにより、試料１、試料３（それぞれの有効成分量は倍量となる）を添加する場合と比較して、たるみ改善に関わる遺伝子発現量が相乗的に向上していた。 As shown in Table 5, by adding sample 7 containing ubiquinone, carnosine and passionflower extract, comparison with the case of adding sample 1 and sample 3 (the amount of each active ingredient is doubled). Therefore, the gene expression level related to the improvement of sagging was synergistically improved.
表６に示した通り、ユビキノン、カルノシン及びザクロ抽出物を含有する試料８を添加することにより、試料１、試料４（それぞれの有効成分量は倍量となる）を添加する場合と比較して、たるみ改善に関わる遺伝子発現量が相乗的に向上していた。 As shown in Table 6, by adding Sample 8 containing ubiquinone, carnosine and pomegranate extract, compared with the case of adding Sample 1 and Sample 4 (the amount of each active ingredient is doubled). , The gene expression level related to the improvement of sagging was synergistically improved.
表７に示した通り、ユビキノン、カルノシン及び酵母エキスを含有する試料９を添加することにより、試料１、試料５（それぞれの有効成分量は倍量となる）を添加する場合と比較して、たるみ改善に関わる遺伝子発現量が相乗的に向上していた。 As shown in Table 7, by adding Sample 9 containing ubiquinone, carnosine and yeast extract, as compared with the case of adding Sample 1 and Sample 5 (the amount of each active ingredient is doubled), The gene expression level related to the improvement of sagging was synergistically improved.
［ヒト線維芽細胞増殖促進作用］
ヒト線維芽細胞を２×１０4個/ウェルとなるように９６ウェルプレートに播種し、０．５％ＦＢＳを含むＤＭＥＭ培地にて一晩培養した。ユビキノン、カルノシン、植物抽出物及び酵母エキスを表８に示した濃度になるように添加した培地に交換し、３７℃、５％ CO2インキュベーター内で２４時間培養した。水溶性テトラゾリウム塩ＷＳＴ−８を発色試薬として用いて各ウェル中の生細胞数を計測した（Cell Counting Kit−８；株式会社同仁化学研究所製）。測定結果をもとに、コントロールにおける生細胞数を１００％として、各群の生細胞数（％）を算出した。なお、細胞増殖率は無添加の場合の細胞増殖数を１００とした相対値で示した。
[Human fibroblast growth promoting action]
Human fibroblasts were seeded in 96-well plates to 2 × 10 4 cells / well and cultured overnight in DMEM medium containing 0.5% FBS. Ubiquinone, carnosine, plant extract and yeast extract were replaced with the medium added to the concentrations shown in Table 8 and cultured at 37 ° C. in a 5% CO 2 incubator for 24 hours. The number of living cells in each well was measured using the water-soluble tetrazolium salt WST-8 as a coloring reagent (Cell Counting Kit-8; manufactured by Dojin Chemical Laboratory Co., Ltd.). Based on the measurement results, the number of viable cells (%) in each group was calculated with the number of viable cells in the control as 100%. The cell proliferation rate was shown as a relative value with the number of cell proliferations when no addition was added as 100.
表８に示した通り、試料１２を添加することにより、試料１０、試料１１（それぞれの有効成分量は倍量となる）を添加する場合と比較して、ヒト線維芽細胞の増殖率が相乗的に向上していた。 As shown in Table 8, by adding sample 12, the proliferation rate of human fibroblasts is synergistic as compared with the case of adding sample 10 and sample 11 (the amount of each active ingredient is doubled). Was improving.
［実施例１］クリーム
（１）スクワラン １０．０（質量％）
（２）ステアリン酸 ２．０
（３）水素添加パーム核油 ０．５
（４）水素添加大豆リン脂質 ０．１
（５）セタノール ３．６
（６）親油型モノステアリン酸グリセリン ２．０
（７）グリセリン １０．０
（８）パラオキシ安息香酸メチル ０．１
（９）アルギニン（２０質量％水溶液） １５．０
（10）精製水 全量を１００とする量
（11）カルボキシビニルポリマー（１質量％水溶液） １５．０
（12）ユビキノン ０．０１
（13）カルノシン ０．０１
（14）トリフルオロアセチルトリペプチド ０．０１
（15）パルミトイルトリペプチド ０．０１
（16）パルミトイルテトラペプチド ０．０１
（17）ハス抽出物 ０．０１
（18）クダモノトケイソウ抽出物 ０．０１
（19）ザクロ抽出物 ０．０１
（20）酵母エキス ０．０１
製法：（１）〜（６）の油相成分を８０℃にて加熱溶解する。一方（７）〜（10）の水相成分を８０℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、（11）を加え、冷却を開始し、４０℃にて（12）〜（20）を加え、均一に混合する。
[Example 1] Cream (1) Squalene 10.0 (mass%)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Parent oil type glycerin monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by mass aqueous solution) 15.0
(10) Amount of purified water totaling 100 (11) Carboxyvinyl polymer (1% by mass aqueous solution) 15.0
(12) Ubiquinone 0.01
(13) Carnosine 0.01
(14) Trifluoroacetyl tripeptide 0.01
(15) Palmitoyl tripeptide 0.01
(16) Palmitoyl tetrapeptide 0.01
(17) Sacred lotus extract 0.01
(18) Passionflower extract 0.01
(19) Pomegranate extract 0.01
(20) Yeast extract 0.01
Production method: The oil phase components of (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added thereto with stirring, and the mixture is uniformly emulsified by a homogenizer. After the emulsification is completed, (11) is added, cooling is started, (12) to (20) are added at 40 ° C., and the mixture is uniformly mixed.
Claims (1)
（Ａ）ユビキノン
（Ｂ）ペプチド
（Ｃ）ハス科ハス属（Nelumbo）植物抽出物、トケイソウ科トケイソウ属（Passiflora）植物抽出物、ザクロ科ザクロ属（Punica）植物抽出物及び酵母エキスから選択される１種又は２種以上 An external preparation for skin containing the following (A) to (C).
(A) Ubiquinone (B) Peptide (C) Lotus family Lotus genus (Nelumbo) plant extract, Passiflora family Passiflora plant extract, Pomegranate family Pomegranate (Punica) plant extract and yeast extract 1 or more
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019038440A JP7356808B2 (en) | 2019-03-04 | 2019-03-04 | Skin external preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019038440A JP7356808B2 (en) | 2019-03-04 | 2019-03-04 | Skin external preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020142995A true JP2020142995A (en) | 2020-09-10 |
| JP7356808B2 JP7356808B2 (en) | 2023-10-05 |
Family
ID=72353213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038440A Active JP7356808B2 (en) | 2019-03-04 | 2019-03-04 | Skin external preparations |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7356808B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116744895A (en) * | 2021-01-22 | 2023-09-12 | 宝洁公司 | Skin care composition containing vitamin B3 in combination with two peptides |
| JP2024501758A (en) * | 2021-01-22 | 2024-01-15 | ザ プロクター アンド ギャンブル カンパニー | Skin care compositions containing a combination of peptides |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040057974A1 (en) * | 2002-08-06 | 2004-03-25 | Naina Sachdev | Antiwrinkle composition and age reversal complex |
| JP2006328024A (en) * | 2005-05-30 | 2006-12-07 | Seiren Co Ltd | Skin care preparation |
| JP2009298738A (en) * | 2008-06-16 | 2009-12-24 | Tsujido Chemical Corp | External preparation for skin |
| JP2011020965A (en) * | 2009-07-17 | 2011-02-03 | Maruzen Pharmaceut Co Ltd | Cosmetic kit, and method of makeup |
| JP2015017081A (en) * | 2013-03-12 | 2015-01-29 | 株式会社東洋新薬 | Aging inhibitor |
| US20160166488A1 (en) * | 2013-02-21 | 2016-06-16 | Gabriele Vielhaber | Medicament |
| WO2017104777A1 (en) * | 2015-12-16 | 2017-06-22 | サントリーホールディングス株式会社 | Composition for inhibiting carnosine dipeptidase |
| US20180371000A1 (en) * | 2015-11-17 | 2018-12-27 | Isp Investments Llc | Process for obtaining an aqueous extract enriched with small rnas from a plant material and extracts resulting from the process |
-
2019
- 2019-03-04 JP JP2019038440A patent/JP7356808B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040057974A1 (en) * | 2002-08-06 | 2004-03-25 | Naina Sachdev | Antiwrinkle composition and age reversal complex |
| JP2006328024A (en) * | 2005-05-30 | 2006-12-07 | Seiren Co Ltd | Skin care preparation |
| JP2009298738A (en) * | 2008-06-16 | 2009-12-24 | Tsujido Chemical Corp | External preparation for skin |
| JP2011020965A (en) * | 2009-07-17 | 2011-02-03 | Maruzen Pharmaceut Co Ltd | Cosmetic kit, and method of makeup |
| US20160166488A1 (en) * | 2013-02-21 | 2016-06-16 | Gabriele Vielhaber | Medicament |
| JP2015017081A (en) * | 2013-03-12 | 2015-01-29 | 株式会社東洋新薬 | Aging inhibitor |
| US20180371000A1 (en) * | 2015-11-17 | 2018-12-27 | Isp Investments Llc | Process for obtaining an aqueous extract enriched with small rnas from a plant material and extracts resulting from the process |
| WO2017104777A1 (en) * | 2015-12-16 | 2017-06-22 | サントリーホールディングス株式会社 | Composition for inhibiting carnosine dipeptidase |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116744895A (en) * | 2021-01-22 | 2023-09-12 | 宝洁公司 | Skin care composition containing vitamin B3 in combination with two peptides |
| JP2024501758A (en) * | 2021-01-22 | 2024-01-15 | ザ プロクター アンド ギャンブル カンパニー | Skin care compositions containing a combination of peptides |
| JP2024501759A (en) * | 2021-01-22 | 2024-01-15 | ザ プロクター アンド ギャンブル カンパニー | Skin care composition containing vitamin B3 in combination with two peptides |
| JP7723099B2 (en) | 2021-01-22 | 2025-08-13 | ザ プロクター アンド ギャンブル カンパニー | Skin care compositions containing peptide combinations |
| JP7741185B2 (en) | 2021-01-22 | 2025-09-17 | ザ プロクター アンド ギャンブル カンパニー | Skin care composition containing vitamin B3 in combination with two peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7356808B2 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100135871A (en) | Active ingredient that stimulates proliferation and / or activity of fibroblasts | |
| WO2017134837A1 (en) | New-hair growth agent | |
| JP2023171950A (en) | Anti-aging agents, antioxidants, anti-inflammatory agents, whitening agents, and cosmetics | |
| JP6154567B2 (en) | Moisturizer, method for producing the same, and cosmetic comprising the moisturizer | |
| KR20210037153A (en) | Cosmetic composition comprising the sprout fermentation and preparation method thereof | |
| KR20240068259A (en) | (functional cosmetic composition | |
| KR102101810B1 (en) | Antiaging cosmetic composition | |
| CN107530273A (en) | Composition containing Valerian root P.E | |
| JP2008184441A (en) | Skin preparation for cell growth promotion | |
| US8808761B2 (en) | Composition of skin external application containing rose extract and epigallocatechin gallate(EGCG) | |
| JP7356808B2 (en) | Skin external preparations | |
| KR20190049067A (en) | A cosmetic composition comprising extract of coffee silver skin and coffee grounds | |
| KR101648148B1 (en) | Cosmetic composition containing fermented graviola for improving anti-wrinkle and method of preparing the same | |
| KR102119511B1 (en) | Functional cosmetic composition | |
| KR102017132B1 (en) | Cosmetic composition comprising a mixed fermentation extract of cinnamomum verum and angelica dahurica | |
| JP6377879B1 (en) | Topical skin preparation | |
| KR102403451B1 (en) | A multifunctional cosmetic composition comprising peptides complex and natural complex extracts | |
| JP2010222273A (en) | Hair nourishing composition | |
| KR102453167B1 (en) | Cosmetic composition for improving skin containing phyto-ceramide | |
| KR102382002B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients | |
| JP2002284648A (en) | Hair restorer composition | |
| CN115737494A (en) | Antioxidant moisturizing skin care product and preparation method thereof | |
| KR102168601B1 (en) | Skincare composition comprising safflower Ferment Extract fermented by Phellinus linteus | |
| KR102688902B1 (en) | Cosmetic composition using unripe citrus unshiu extract containing citrus bio-gel | |
| KR101182743B1 (en) | Producing method of lacquer tree extraction removing urushiol using grifola frondosa and cosmetic compositon for preventing falling out of the hair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210825 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230627 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230706 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230919 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230925 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7356808 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |